Latest News

FDA: No Unexpected Safety Risks Associated With Pimavanserin
The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.
Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.
The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.
Top news of the day from across the health care landscape.
Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases
Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.
Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Features

With American Patients First, the administration is doing its part to improve prescription drug affordability—now it’s time for Congress to do theirs.
As specialty spending continues to creep up to 50% of total drug spend, payers have an option to directly reduce their costs while impacting a relatively small volume of prescriptions.
By establishing in-house specialty pharmacies, health systems can accelerate growth while offering patients innovative therapies, an enhanced experience, and clinically coordinated care that ultimately improves outcomes.
There has been increasing buzz surrounding health care reform concepts that which seek to address the singular issue of individual health care coverage affordability.

Featured Company Profile

 
MHA Specialty Pharmacy Solutions: Patient Engagement Strategies for Your Pharmacy

Videos

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, talks about why pharmacists should pursue continuing education to benefit their patients.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the potential for specialty pharmacies to become the norm.

Current Issue

September/October
Volume: 9
Number: 6

Most Popular

Previous TabNext Tab
Strategic Alliance Partners
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$